|
Ozempic and Wegovy GLP-1 Drugs
Ankin Law is actively seeking individuals who have been injured after having been prescribed and taking GLP-1 drugs for weight-loss and manufactured by Novo Nordisk or Eli Lilly. Including, Ozempic®, Wegovy®, Mounjaro®, Rybelsus®, Saxenda®, Trulicity®, Victoza®, or Zepbound®
Thousands of people who took Ozempic®, Wegovy®, or other GLP-1 weight-loss drugs made by Novo Nordisk or Eli Lilly have reported severe stomach, digestive, and vision issues — and in some cases, permanent injuries. In addition, current lawsuits allege that Novo Nordisk and its competitors failed to warn consumers about the potential risks of using these drugs.
Reported Issues experienced by plaintiffs:
Severe Stomach or Digestive Issues
- Gastroparesis (stomach paralysis): This is the most widely cited claim. In gastroparesis, the stomach muscles slow down or stop working, leading to chronic vomiting, nausea, bloating, and malnutrition.
-
Intestinal blockages (ileus): This condition occurs when the intestines fail to function correctly, resulting in severe pain and blockages. The FDA added ileus on Ozempic's label in 2023.
- Necrotizing pancreatitis (pancreas inflammation)
- Gallbladder removal after taking the drug (prior to March, 2022)
Vision Injuries
- Sudden blindness or severe vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)
- Optic or retinal stroke
- Optic nerve damage or ischemia
- Wet macular degeneration
- (Not including floaters, diabetic retinopathy, cataracts, or glaucoma.)
If you were prescribed and took a brand-name GLP-1 drug, not a compounded or “generic” version, and have experienced any of the above issues, contact Ankin Law for information to see if you qualify. Call 312.600.0000
For more information on GLP-1 drugs like Ozempic and Wegovy click here.
|